Rafael Holdings, Inc. (RFL)
$
1.95
+0.06 (3.08%)
Key metrics
Financial statements
Free cash flow per share
-0.4541
Market cap
94.7 Million
Price to sales ratio
129.3256
Debt to equity
0.0086
Current ratio
3.8480
Income quality
0.4878
Average inventory
144 Thousand
ROE
-0.2996
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Rafael Holdings, Inc. operates in the pharmaceuticals and real estate sectors, holding interests in clinical and early-stage pharmaceutical companies as well as commercial real estate assets in the United States and Israel. The company engages in the leasing of a commercial office building alongside an 800-car public garage, while also focusing on the development and commercialization of therapies targeting the metabolic disparities between normal and cancerous cells. The earnings per share (EPS) is reported at -$1.45 indicating the company's profitability on a per-share basis. Additionally, the operating expenses amount to $103,110,000.00 encompassing a variety of operational costs incurred by the firm. The net total of other income and expenses is $35,366,000.00 reflecting its non-core financial activities. A crucial measure of its financial health, the EBITDA is -$66,788,000.00 representing the company's operational profitability. Moreover, the operating income ratio is -$161.11 which showcases the company's operational profitability margin as it aims to enhance its market position through innovative therapies. The company’s lead drug candidate, CPI-613 (devimistat), is undergoing various clinical studies, including two Phase III registrational trials targeting metastatic pancreatic cancer and relapsed/refractory acute myeloid leukemia, solidifying its commitment to addressing critical health challenges. On the market front, Rafael Holdings presents a stock that is affordable at $1.95 making it an appealing option for budget-conscious investors. However, the stock has a low average trading volume of 234,285.00 indicating lower market activity, which could affect liquidity. With a market capitalization of $97,671,600.00 the company is classified as a small-cap player in the industry, where it is recognized as a key contributor to the overall market landscape. It operates within the Real Estate sector, driving innovation and growth, and highlighting its strategic focus on creating therapies that promise to significantly improve patient outcomes. By maintaining its position in this dynamic industry, Rafael Holdings continues to attract attention from investors seeking exposure to both pharmaceuticals and real estate opportunities, which together form a robust portfolio aimed at long-term value creation.
Investing in Rafael Holdings, Inc. (RFL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Rafael Holdings, Inc. stock to fluctuate between $1.27 (low) and $3.19 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-07, Rafael Holdings, Inc.'s market cap is $97,671,600, based on 50,088,000 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Rafael Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
Rafael Holdings, Inc. pays dividends. The current dividend yield is 0.41%, with a payout of $0.02 per share.
To buy Rafael Holdings, Inc. (RFL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for RFL. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Rafael Holdings, Inc.'s last stock split was 507:500 on 2025-05-09.
Revenue: $637,000 | EPS: -$1.45 | Growth: 1,699.01%.
Visit https://www.rafaelholdings.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $66.44 (2021-07-06) | All-time low: $1.28 (2025-05-21).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
14 days ago
TAMPA, Fla.--(BUSINESS WIRE)--Bloomin' Brands, Inc. (Nasdaq: BLMN) announced the appointment of Rafael Sanchez as Senior Vice President & Chief Information Officer. Sanchez joins the company from Davidson Hospitality Group where he served as Senior Vice President of Information Technology. His appointment is effective June 30, 2025. “Rafael has a strong history in out-of-home entertainment and restaurants,” said Mike Spanos, CEO of Bloomin' Brands, Inc. “He is a strong leader that focuses o.
globenewswire.com
a month ago
NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025.
globenewswire.com
a month ago
NEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today the final results and closing of its $25.0 million rights offering (the “Rights Offering”). The subscription period of the Rights Offering expired at 5:00 P.M. Eastern Time, on May 29, 2025. The Rights Offering resulted in subscriptions for 3,130,480 shares of Class B common stock at an exercise price of $1.28 per share for aggregate gross proceeds of $4,007,014.40.The subscriptions do not reflect subscription rights held by Howard Jonas, Chief Executive Officer, President and Executive Chairman of the Company and Chairman of the Board of Directors of the Company, and his affiliates who held, prior to the rights offering, approximately 32% of the outstanding common stock of the Company. Due to Mr. Jonas' previously disclosed commitment to backstop the Rights Offering through a private placement of shares in the event that the Rights Offering was not fully subscribed (the “Backstop Private Placement”), those holders did not exercise their subscription rights. Mr. Jonas and certain related parties are purchasing the unsubscribed shares for an aggregate amount of $20,992,985.60.
globenewswire.com
2 months ago
NEWARK, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today provided an update to the subscription rights related to its Public Warrants in connection with its previously announced rights offering.
prnewswire.com
2 months ago
DALLAS , May 19, 2025 /PRNewswire/ -- Texas Instruments Incorporated (TI) (Nasdaq: TXN) Senior Vice President and Chief Financial Officer Rafael Lizardi will speak at the Bank of America 2025 Global Technology Conference in San Francisco on Wednesday, June 4, at 11:20 a.m. Pacific time.
globenewswire.com
2 months ago
NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced revised subscription rights in connection with its previously announced rights offering.
globenewswire.com
2 months ago
NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants (“Holders”) the opportunity to purchase additional shares of Rafael Holdings' Class B common stock, par value $0.01 per share (“Class B Common Stock”), subject to the terms outlined below for an aggregate offering of $25 million. The funds provide the Company additional capital for the potential launch of Trappsol® Cyclo™ in the event of a positive interim result from the 48-week interim analysis of the TransportNPC™ Phase 3 clinical trial in Niemann-Pick Disease Type C1 (“NPC1”).
globenewswire.com
2 months ago
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
globenewswire.com
3 months ago
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
globenewswire.com
4 months ago
The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol ® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025.
See all news